Review ArticleMolecular Imaging of Newly Diagnosed Prostate CancerWilliams, Scott MD, MBBS, FRANZCRAuthor Information From the Division of Radiation Oncology, Peter MacCallum Cancer Centre; and Division of Radiation Oncology, University of Melbourne, Melbourne, Victoria, Australia. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Scott Williams, MD, MBBS, FRANZCR, Division of Radiation Oncology, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, Victoria 3000 Australia. E-mail: Scott.Williams@petermac.org. The Cancer Journal: January/February 2020 - Volume 26 - Issue 1 - p 43-47 doi: 10.1097/PPO.0000000000000427 Buy Metrics Abstract Positron emission tomography (PET) is a valuable imaging in evaluating many malignancies. There are various molecular imaging tracers that are currently being utilized with prostate cancer (PC). Several PET agents imaging different molecular processes in PC have reached the clinic. While all of these agents have demonstrated an advantage over conventional imaging, there are considerable differences in the performance of each in staging newly diagnosed PC. In this article, we review the current updates available of different PET tracers, with a strong focus on the emerging role of prostate-specific membrane antigen PET in the management of newly diagnosed PC. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.